Lunai Bioworks Stock (NASDAQ:RENB)
Previous Close
$1.42
52W Range
$1.12 - $21.00
50D Avg
$1.96
200D Avg
$4.41
Market Cap
$32.92M
Avg Vol (3M)
$218.51K
Beta
0.53
Div Yield
-
RENB Company Profile
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.